NCT05459727

Brief Summary

This study is to evaluate whether non-surgical periodontal therapy can help to control the cardiovascular risk among patients with moderate/severe periodontitis and at risk of cardiovascular disease.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
376

participants targeted

Target at P75+ for not_applicable cardiovascular-diseases

Timeline
7mo left

Started Aug 2022

Longer than P75 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Aug 2022Dec 2026

First Submitted

Initial submission to the registry

July 5, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 15, 2022

Completed
17 days until next milestone

Study Start

First participant enrolled

August 1, 2022

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2025

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

July 15, 2022

Status Verified

May 1, 2022

Enrollment Period

3.1 years

First QC Date

July 5, 2022

Last Update Submit

July 12, 2022

Conditions

Keywords

PeriodontitisNon-surgical Periodontal TherapyCardiovascular risk

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline Cardiovascular risk (Framingham risk score (FRS)) at 1 year.

    Cardiovascular risk is assessed by "Framingham risk score (FRS)". (Circulation, 2008,117(6): 743-753.) Generally, the "Framingham risk score (FRS)" ranges from -4 to 33 for men and -5 to 33 for women. A higher "Framingham risk score (FRS)" means a higher risk of developing cardiovascular disease.

    Baseline; 1 year

Secondary Outcomes (16)

  • Change from baseline systolic blood pressure at 1 year after enrollment.

    Baseline; 1 year

  • Change from baseline diastolic blood pressure at 1 year after enrollment.

    Baseline; 1 year

  • Change from baseline fasting blood glucose at 1 year after enrollment.

    Baseline; 1 year

  • Change from baseline glycosylated hemoglobin at 1 year after enrollment.

    Baseline; 1 year

  • Change from baseline total cholesterol at 1 year after enrollment.

    Baseline; 1 year

  • +11 more secondary outcomes

Study Arms (2)

Intervention arm

EXPERIMENTAL

1. Basic oral hygiene instructions. 2. Full-mouth subgingival scaling and root planing under local anesthesia. 3. Additional full-mouth subgingival scaling and root planing under local anesthesia every 3 months during the follow-up period if necessary.

Procedure: Non-surgical periodontal therapy

Control arm

PLACEBO COMPARATOR

1. Basic oral hygiene instructions. 2. Full-mouth supragingival ultrasonic scaling.

Procedure: Control periodontal treatment

Interventions

Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.

Intervention arm

Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.

Control arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years;
  • At risk of cardiovascular disease (defined as "Framingham Score" predicted 10-year risk of cardiovascular disease ≥ 20%);
  • Moderate//severe periodontitis;

You may not qualify if:

  • Cardiovascular diseases at baseline (coronary heart disease, stroke and peripheral artery disease);
  • Received periodontal treatment within the past 6 months;
  • Pregnant or lactating females;
  • Non residents of Guangzhou and its surrounding cities or expected to leave Guangzhou or its surrounding cities within 1 year;
  • Malignant tumors or other end-stage diseases with life expectancy less than 1 year;
  • End-stage renal disease;
  • Patients with high bleeding risk, high blood pressures or other situations that make them unable to receive interventions;
  • Refuse to provide informed consent;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Stomatological Hospital, Southern Medical University

Guangzhou, Guangdong, 510280, China

Location

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China

Location

MeSH Terms

Conditions

Cardiovascular DiseasesPeriodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • Jiancheng Xiu, MD

    Nanfang Hospital, Southern Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jiancheng Xiu, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Due to the characteristics of the intervention in this trial, it would be impossible to blind the enrolled participants. However, the investigators and outcomes assessors will be blinded. Allocation to arms will be concealed in an envelope and revealed to the stomatologist and patient before delivering the first treatment. Other investigators like outcomes assessors and staff involved in the data collection and analyses will be masked.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 5, 2022

First Posted

July 15, 2022

Study Start

August 1, 2022

Primary Completion

August 31, 2025

Study Completion (Estimated)

December 31, 2026

Last Updated

July 15, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations